{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-003646","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.682196+00:00","generated_at":"2026-06-19T08:37:24.241824+00:00","sec_items":["1.02","2.05","5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Diffusion cuts nearly half of staff, pauses lead drug study; CMO departs","bullets":["Reduction in force affecting 6 of 13 employees (~46% cut) as cash preservation measure.","Company pauses Phase 2 study of TSC in newly diagnosed GBM; evaluating sale or out-license of TSC.","Expects $1.1M one-time charge in Q1 2023 for termination benefits.","Chief Medical Officer Dr. Christopher Galloway departs effective March 1, 2023; separation includes 9 months salary, pro-rated bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-003646","json":"https://secwatch.observer/filing/0001437749-23-003646.json","markdown":"https://secwatch.observer/filing/0001437749-23-003646.md","text":"https://secwatch.observer/filing/0001437749-23-003646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/0001437749-23-003646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/dffn20230216_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:37:24.241824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8882eb024","claim":"Christopher D. Galloway departed as Chief Medical Officer at CervoMed Inc..","evidence_excerpt":"As part of the reduction in force, the Company determined that Dr. Christopher D. Galloway, M.D., the Company’s Chief Medical Officer, will depart Diffusion effective March 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/0001437749-23-003646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"833e84ba4e5126665d8e366df27dfd9ac27fc3d2","claim":"CervoMed Inc. announced a restructuring with charges of approximately $1.1 million affecting clinical operations function (six of the Company’s 13 current employees).","evidence_excerpt":"Diffusion expects to record a one-time charge of approximately $1.1 million in the first quarter of 2023 in connection with the reduction in force, primarily related to one-time termination benefits to be paid in cash, which is expected to be completed in March 2023.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/0001437749-23-003646-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.1 million"},{"label":"Affected area","value":"clinical operations function"},{"label":"Headcount","value":"six of the Company’s 13 current employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}